Leena Suojala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leena Suojala has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Heli Simojoki
Department of Production Animal Medicine, University of Helsinki, Paroninkuja 20, 04920 Saarentaus, Finland
2 shared publications Anna Pitkälä
1 shared publicationAnna-Liisa Myllyniemi
1 shared publication- Hanna Järvinen
Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, FI-04920 Saarentaus, Finland
1 shared publication - Johanna Saatsi
Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, FI-04920 Saarentaus, Finland
1 shared publication K. Mustonen
1 shared publication
Latest Publications
- 1 January 2011
- Published by Elsevier in Veterinary Microbiology
- Vol. 147 (3-4) , 383-388
Phylogeny, virulence factors and antimicrobial susceptibility of Escherichia coli isolated in clinical bovine mastitis
- 1 January 2011
- Published by Elsevier in Veterinary Microbiology
- Vol. 147 (3-4) , 383-388
Phylogeny, virulence factors and antimicrobial susceptibility of Escherichia coli isolated in clinical bovine mastitis
- 1 May 2010
- Published by American Dairy Science Association in Journal of Dairy Science
- Vol. 93 (5) , 1960-1969
Efficacy of enrofloxacin in the treatment of naturally occurring acute clinical Escherichia coli mastitis
The efficacy of the combination of systemic enrofloxacin (5mg/kg twice with a 24-h interval, first dose i.v., second dose s.c.) and the nonsteroidal antiinflammatory agent ketoprofen (3mg/kg i.m. or 4 mg/kg per os daily for 1 to 3 d) treatment was compared with antiinflammatory treatment only in dairy cows with naturally occurring acute clinical Escherichia coli mastitis. A total of 132 cows with acute clinical mastitis and with confirmed growth of E. coli in a pretreatment milk sample were randomly allocated to 1 of 2 treatment groups. Response to treatment was evaluated clinically and by bacteriological culturing and determination of N-acetyl-beta-d-glucosaminidase (NAGase) activity on d 2 and 21 posttreatment. Enrofloxacin treatment did not increase bacteriological (90.5% of treated vs. 86.8% of nontreated cured) or clinical cure (46.7% of treated vs. 57.1% of nontreated cured), cow survival (95.3% of treated vs. 92.7% of nontreated), or quarter milk production assessed 21 d posttreatment (21.8 vs. 29.3% return to preinfection level for nontreated cows), nor did it decrease mammary gland tissue damage estimated using determination of milk NAGase activity (24.0+/-0.3 vs. 18.3+/-1.3 pmol of 4-methylumbelliferone per min per microL for nontreated cows). Treatment did not influence the number of study cows remaining in the herd after 6 mo (71.9% of treated vs. 80.6% of nontreated). The only significant effects of enrofloxacin were enhancing the bacteriological cure (odds ratio=3.32 for treated cows) and decreasing the clinical cure (odds ratio=0.05 for treated cows) on d 2 posttreatment. Our results did not support the use of enrofloxacin to treat acute clinical E. coli mastitis.
- 1 May 2010
- Published by American Dairy Science Association in Journal of Dairy Science
- Vol. 93 (5) , 1960-1969
Efficacy of enrofloxacin in the treatment of naturally occurring acute clinical Escherichia coli mastitis
The efficacy of the combination of systemic enrofloxacin (5mg/kg twice with a 24-h interval, first dose i.v., second dose s.c.) and the nonsteroidal antiinflammatory agent ketoprofen (3mg/kg i.m. or 4 mg/kg per os daily for 1 to 3 d) treatment was compared with antiinflammatory treatment only in dairy cows with naturally occurring acute clinical Escherichia coli mastitis. A total of 132 cows with acute clinical mastitis and with confirmed growth of E. coli in a pretreatment milk sample were randomly allocated to 1 of 2 treatment groups. Response to treatment was evaluated clinically and by bacteriological culturing and determination of N-acetyl-beta-d-glucosaminidase (NAGase) activity on d 2 and 21 posttreatment. Enrofloxacin treatment did not increase bacteriological (90.5% of treated vs. 86.8% of nontreated cured) or clinical cure (46.7% of treated vs. 57.1% of nontreated cured), cow survival (95.3% of treated vs. 92.7% of nontreated), or quarter milk production assessed 21 d posttreatment (21.8 vs. 29.3% return to preinfection level for nontreated cows), nor did it decrease mammary gland tissue damage estimated using determination of milk NAGase activity (24.0+/-0.3 vs. 18.3+/-1.3 pmol of 4-methylumbelliferone per min per microL for nontreated cows). Treatment did not influence the number of study cows remaining in the herd after 6 mo (71.9% of treated vs. 80.6% of nontreated). The only significant effects of enrofloxacin were enhancing the bacteriological cure (odds ratio=3.32 for treated cows) and decreasing the clinical cure (odds ratio=0.05 for treated cows) on d 2 posttreatment. Our results did not support the use of enrofloxacin to treat acute clinical E. coli mastitis.
- Open Access
- 13 June 2008
- Published by Springer Nature in Acta Veterinaria Scandinavica
- Vol. 50 (1) , 18
Acute phase response in two consecutive experimentally induced E. coli intramammary infections in dairy cows
Acute phase proteins haptoglobin (Hp), serum amyloid A (SAA) and lipopolysaccharide binding protein (LBP) have suggested to be suitable inflammatory markers for bovine mastitis. The aim of the study was to investigate acute phase markers along with clinical parameters in two consecutive intramammary challenges with Escherichia coli and to evaluate the possible carry-over effect when same animals are used in an experimental model.
- 13 June 2008
- Published by Springer Nature in Acta Veterinaria Scandinavica
- Vol. 50 (1) , 18
Open AccessAcute phase response in two consecutive experimentally induced E. coli intramammary infections in dairy cows
Acute phase proteins haptoglobin (Hp), serum amyloid A (SAA) and lipopolysaccharide binding protein (LBP) have suggested to be suitable inflammatory markers for bovine mastitis. The aim of the study was to investigate acute phase markers along with clinical parameters in two consecutive intramammary challenges with Escherichia coli and to evaluate the possible carry-over effect when same animals are used in an experimental model.